Equities Analysts Issue Forecasts for Genmab A/S Q4 Earnings

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Equities researchers at HC Wainwright increased their Q4 2026 earnings estimates for Genmab A/S in a research report issued to clients and investors on Thursday, October 29th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.46 per share for the quarter, up from their prior forecast of $0.46. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Genmab A/S’s Q1 2027 earnings at $0.35 EPS, Q2 2027 earnings at $0.59 EPS, Q3 2027 earnings at $0.61 EPS and Q4 2027 earnings at $0.61 EPS.

A number of other equities analysts also recently issued reports on GMAB. Guggenheim raised their price target on Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. JPMorgan Chase & Co. upgraded Genmab A/S from a “neutral” rating to an “overweight” rating in a research report on Monday. Weiss Ratings raised Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. Morgan Stanley set a $42.00 target price on Genmab A/S in a report on Tuesday, October 20th. Finally, TD Cowen raised their target price on Genmab A/S from $43.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.06.

Genmab A/S Price Performance

Shares of GMAB opened at $56.49 on Friday. The firm has a market cap of $35.25 billion, a PE ratio of 41.22, a P/E/G ratio of 2.47 and a beta of 0.81. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. The firm has a fifty day simple moving average of $36.64 and a two-hundred day simple moving average of $30.47. Genmab A/S has a 1-year low of $23.62 and a 1-year high of $59.97.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.12 billion.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds have recently modified their holdings of GMAB. WINTON GROUP Ltd increased its holdings in Genmab A/S by 158.9% in the 2nd quarter. WINTON GROUP Ltd now owns 40,900 shares of the company’s stock worth $1,124,000 after acquiring an additional 25,100 shares in the last quarter. Diversify Wealth Management LLC bought a new stake in Genmab A/S during the 1st quarter worth approximately $1,216,000. SummitTX Capital L.P. bought a new stake in Genmab A/S during the 1st quarter worth approximately $2,263,000. Legacy Wealth Asset Management LLC lifted its holdings in Genmab A/S by 164.1% during the second quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock valued at $2,806,000 after purchasing an additional 63,484 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Genmab A/S during the first quarter valued at approximately $1,198,000. Institutional investors own 7.07% of the company’s stock.

Key Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Genmab reported that its Phase 3 LiGeR-HN1 trial met both primary endpoints. Petosemtamab combined with Merck’s Keytruda significantly improved overall survival and objective response in first-line PD-L1-positive recurrent or metastatic head and neck cancer, cutting the risk of death by 50% versus Keytruda alone. Genmab plans to discuss the results with regulators, supporting the drug’s potential commercial value. Genmab Phase 3 LiGeR-HN1 trial announcement
• Positive Sentiment: Analysts remain constructive following the trial data. Truist reaffirmed a Buy rating and raised its price target to $67 from $45, while HC Wainwright lifted its target to $70 from $50 and maintained its Buy rating. These targets imply additional upside from recent trading levels. HC Wainwright analyst action
• Neutral Sentiment: HC Wainwright’s updated quarterly EPS forecasts were essentially unchanged, with small increases for the fourth quarter of 2026 and the third and fourth quarters of 2027 offset by minor reductions for the first and second quarters of 2027. The firm still expects $1.22 in full-year EPS and retains its Buy rating. Genmab analyst estimates
• Negative Sentiment: After reaching record or 52-week highs on the trial announcement, valuation and near-term profit-taking may be weighing on the shares. Commentary has cautioned investors about buying immediately after the strong run, despite describing the clinical results as compelling. Genmab valuation commentary

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.